Projects per year
The Cardiac CARE trial is a multicentre prospective randomized open label blinded endpoint trial of combination beta-adrenergic receptor blocker and renin-angiotensin-system inhibitor therapy in patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy that is associated with myocardial injury. Patients at higher risk of cardiotoxicity with plasma high sensitivity cardiac troponin I concentrations in the upper tertile at the end of chemotherapy are randomized to standard of care plus combination candesartan and carvedilol therapy or standard of care alone. All patients undergo cardiac magnetic resonance imaging before and 6 months after anthracycline treatment. The primary endpoint is the change in left ventricular ejection fraction at 6 months after chemotherapy. In low-risk non-randomized patients, left ventricular ejection fraction before and 6 months after anthracycline will be compared to define the specificity of the high-sensitivity cardiac troponin I assay for identifying low-risk participants who do not develop left ventricular systolic dysfunction.
Discussion: Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients.
|Journal||Circulation: Heart failure|
|Publication status||Published - 29 Jun 2022|